We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Eric Jonasch

Eric Jonasch MD

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine; Director, VHL Clinical Center, The University of Texas MD Anderson Cancer Center, Houston, Texas

Biographical Sketch:

Eric Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at the MD Anderson Cancer Center of The University of Texas in Houston, where he is also Co-Chair of the Renal Cancer Program. Since 2003, Dr. Jonasch has been the Director of the Von Hippel Lindau (VHL) Clinical Center in Houston. He performs clinical, translational, and basic research in VHL disease and kidney cancer.

After receiving his MDCM degree from McGill University Faculty of Medicine, Dr. Jonasch underwent clinical residency in internal medicine at the Royal Victoria Hospital in Montreal. Subsequently, he completed a research fellowship in Hematology/Oncology at the New England Medical Center in Boston, as well as a clinical fellowship. He was then awarded a research fellowship at the Beth Israel Deaconess Medical Center in Boston.

Dr. Jonasch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Urological Association, and the National Comprehensive Cancer Network. He serves as a board member and Director of the Clinical Advisory and Research Councils of the VHL Alliance and serves on the Medical Advisory Board of the Kidney Cancer Association; he is a member of the NCI PDQ Cancer Genetics Editorial Board.

Additionally, Dr. Jonasch has published widely in many peer-reviewed journals and has contributed to and published various books.

Positions:

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center

Director, VHL Clinical Center, MD Anderson Cancer Center

Co-Chair, Renal Cancer Program, MD Anderson Cancer Center

Consultantships:

Board Member and Director of Clinical Advisory and Research Councils, VHL Alliance, Boston, Massachusetts

Member, Kidney Cancer Association Medical Advisory Board, Chicago, Illinois

Member, NCI PDQ Cancer Genetics Editorial Board

Vice Chair, Kidney/Testicular Cancers Panel, National Comprehensive Cancer Network

Degree:

McGill University Faculty of Medicine, MDCM

Postgraduate Training:

Postdoctoral research fellow, Beth Israel Deaconess Medical Center, Boston
Postdoctoral clinical fellow, New England Medical Center, Boston
Postdoctoral research fellow, Hematology/Oncology, New England Medical Center, Boston

Board Certifications:

Medical Oncology, American Board of Internal Medicine
Oncology, Royal College of Physicians & Surgeons of Canada
Medicine, Royal College of Physicians & Surgeons of Canada
Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine

Disclosures

Eric Jonasch MD serves as a consultant to Bristol-Myers Squibb Company, Pfizer Inc. Glaxo SmithKline plc, Novartis AG, Exelixis Inc, Cerulean Inc. and Genentech Inc.; and has received research/grant support from Exelixis Inc, Pfizer Inc., and Novartis AG.